1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Tesaro Pumped As PARP Inhibitor Zejula Gets CHMP Nod

 
• By Kevin Grogan

While AstraZeneca's rival drug Lynparza is catching up across the Atlantic, this likely approval for Tesaro's ovarian cancer drug will boost the US firm as it aims to make a strong start in the European market.

Female Reproductive System_1200
Zejula is set for EU approval in ovarian cancer

Tesaro Inc. has stolen a march on its competitors in the PARP inhibitor space, having received a recommendation for approval for Zejula (niraparib) as maintenance therapy in ovarian cancer from advisors to the European Medicines Agency.

Specifically, the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion for Zejula as a monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (PR) to platinum-based chemotherapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.